Influence of inflammatory cytokine polymorphisms on eradication rates of helicobacter pylori

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 11, 2009, Pages 1725-1732

  Sugimoto, Mitsushige ^a,b   Furuta, Takahisa ^b   Yamaoka, Yoshio ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OITA UNIVERSITY   (Japan)

Author keywords

Eradication therapy; Helicobacter pylori; IL 1 ; Inflammatory cytokine; Polymorphism; TNF

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOKINE; INTERLEUKIN 1BETA; LANSOPRAZOLE; MESSENGER RNA; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TINIDAZOLE; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC RESISTANCE; ERADICATION THERAPY; GENE; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IL 10 GENE; IL 1RN GENE; INFLAMMATION; INFLAMMATORY CELL; MUCOSA INFLAMMATION; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STOMACH ACID SECRETION; STOMACH MUCOSA; STOMACH PH; TNF A GENE;

EID: 70449377200     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.06047.x     Document Type: Review

References (74)

1. Falush D, Wirth T, Linz B et al. Traces of human migrations in Helicobacter pylori populations. Science 2003 299 : 1582 1585.
2. Moodley Y, Linz B, Yamaoka Y et al. The peopling of the Pacific from a bacterial perspective. Science 2009 323 : 527 530.
3. Yamaoka Y, Orito E, Mizokami M et al. Helicobacter pylori in North and South America before Columbus. FEBS Lett. 2002 517 : 180 184.
4. Van Doorn LJ, Figueiredo C, Megraud F et al. Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology 1999 116 : 823 830.
5. Sugimoto M, Yamaoka Y. The association of vacA genotype and Helicobacter pylori-related disease in Latin American and African populations. Clin. Microbiol. Infect. 2009 15 : 835 842.
6. Uemura N, Okamoto S, Yamamoto S et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001 345 : 784 789.
7. Wong BC, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: A randomized controlled trial. JAMA 2004 291 : 187 194.
8. Take S, Mizuno M, Ishiki K et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am. J. Gastroenterol. 2005 100 : 1037 1042.
9. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: A review. Gastroenterology 1996 110 : 1244 1252.
10. Uemura N, Mukai T, Okamoto S et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol. Biomarkers Prev. 1997 6 : 639 642.
11. Wotherspoon AC, Doglioni C, de Boni M, Spencer J, Isaacson PG. Antibiotic treatment for low-grade gastric MALT lymphoma. Lancet 1994 343 : 1503.
12. Sugimoto M, Kajimura M, Shirai N et al. Outcome of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Intern. Med. 2006 45 : 405 409.
13. Fukase K, Kato M, Kikuchi S et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet 2008 372 : 392 397.
14. Furuta T, Ohashi K, Kosuge K et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 1999 65 : 552 561.
15. Graham DY, Lu H, Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: Sequential therapy and beyond. Drugs 2008 68 : 725 736.
16. Kamada T, Haruma K, Komoto K et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter 1999 4 : 204 210.
17. Sugimoto M, Yamaoka Y. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch. Immunol Ther. Exp. (Warsz) 2009 57 : 45 56.
18. Furuta T, Shirai N, Kodaira M et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin. Pharmacol. Ther. 2007 81 : 521 528.
19. Sugimoto M, Furuta T, Shirai N et al. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert. Opin. Pharmacother. 2007 8 : 2701 2717.
20. Sugimoto M, Furuta T, Shirai N et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007 12 : 317 323.
21. Broutet N, Tchamgoue S, Pereira E, Lamouliatte H, Salamon R, Megraud F. Risk factors for failure of Helicobacter pylori therapy - results of an individual data analysis of 2751 patients. Aliment. Pharmacol. Ther. 2003 17 : 99 109.
22. van der Hulst RW, Weel JF, Verheul SB et al. Treatment of Helicobacter pylori infection with low or high dose omeprazole combined with amoxycillin and the effect of early retreatment. Aliment. Pharmacol. Ther. 1996 10 : 165 171.
23. Yamaoka Y, Kita M, Kodama T, Sawai N, Imanishi J. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroenterology 1996 110 : 1744 1752.
24. Yamaoka Y, Kodama T, Gutierrez O, Kim JG, Kashima K, Graham DY. Relationship between Helicobacter pylori iceA, cagA, and vacA status and clinical outcome: Studies in four different countries. J. Clin. Microbiol. 1999 37 : 2274 2279.
25. Wolfe MM, Nompleggi DJ. Cytokine inhibition of gastric acid secretion - a little goes a long way. Gastroenterology 1992 102 : 2177 2178.
26. Takashima M, Furuta T, Hanai H, Sugimura H, Kaneko E. Effects of Helicobacter pylori infection on gastric acid secretion and serum gastrin levels in Mongolian gerbils. Gut 2001 48 : 765 773.
27. Wang M, Furuta T, Takashima M et al. Relation between interleukin-1beta messenger RNA in gastric fundic mucosa and gastric juice pH in patients infected with Helicobacter pylori. J. Gastroenterol. 1999 34 (Suppl. 11 10 17. (Pubitemid 30072480)
28. Furuta T, Shirai N, Takashima M, Xiao F, Sugimura H. Effect of genotypic differences in interleukin-1 beta on gastric acid secretion in Japanese patients infected with Helicobacter pylori. Am. J. Med. 2002 112 : 141 143.
29. Furuta T, El-Omar EM, Xiao F et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002 123 : 92 105.
30. Take S, Mizuno M, Ishiki K et al. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am. J. Gastroenterol. 2003 98 : 2403 2408.
31. Furuta T, Shirai N, Xiao F et al. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clin. Gastroenterol. Hepatol. 2004 2 : 22 30.
32. Sugimoto M, Furuta T, Shirai N, Ikuma M, Hishida A, Ishizaki T. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clin. Pharmacol. Ther. 2006 80 : 41 50.
33. Zambon CF, Fasolo M, Basso D et al. Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success. J. Gastrointest. Surg. 2007 11 : 1506 1514 discussion 1514.
34. Fridman WH, Tartour E. Cytokines and cell regulation. Mol. Aspects Med. 1997 18 : 3 90.
35. Hwang IR, Kodama T, Kikuchi S et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 2002 123 : 1793 1803. (Pubitemid 35408303)
36. Kondo S, Shinomura Y, Kanayama S et al. Interleukin-1 beta inhibits gastric histamine secretion and synthesis in the rat. Am. J. Physiol. 1994 267 : G966 71.
37. El-Omar EM, Carrington M, Chow WH et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000 404 : 398 402.
38. Saperas ES, Yang H, Rivier C, Tache Y. Central action of recombinant interleukin-1 to inhibit acid secretion in rats. Gastroenterology 1990 99 : 1599 1606.
39. Weigert N, Schaffer K, Schusdziarra V, Classen M, Schepp W. Gastrin secretion from primary cultures of rabbit antral G cells: Stimulation by inflammatory cytokines. Gastroenterology 1996 110 : 147 154.
40. Prinz C, Neumayer N, Mahr S, Classen M, Schepp W. Functional impairment of rat enterochromaffin-like cells by interleukin 1 beta. Gastroenterology 1997 112 : 364 375.
41. Beales IL, Calam J. Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 1998 42 : 227 234.
42. Stokkers PC, van Aken BE, Basoski N, Reitsma PH, Tytgat GN, van Deventer SJ. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut 1998 43 : 33 9.
43. Tarlow JK, Blakemore AI, Lennard A et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum. Genet. 1993 91 : 403 404.
44. Kato S, Onda M, Yamada S, Matsuda N, Tokunaga A, Matsukura N. Association of the interleukin-1 beta genetic polymorphism and gastric cancer risk in Japanese. J. Gastroenterol. 2001 36 : 696 699.
45. Machado JC, Pharoah P, Sousa S et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001 121 : 823 829.
46. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 1997 34 : 391 399.
47. Negoro K, Kinouchi Y, Hiwatashi N et al. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 1999 117 : 1062 1068.
48. Sugimoto M, Furuta T, Shirai N et al. Different effects of polymorphisms of tumor necrosis factor-alpha and interleukin-1 beta on development of peptic ulcer and gastric cancer. J. Gastroenterol. Hepatol. 2007 22 : 51 9.
49. Ohyama I, Ohmiya N, Niwa Y et al. The association between tumour necrosis factor-alpha gene polymorphism and the susceptibility to rugal hyperplastic gastritis and gastric carcinoma. Eur. J. Gastroenterol. Hepatol. 2004 16 : 693 700.
50. Zambon CF, Basso D, Navaglia F et al. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine 2005 29 : 141 152.
51. Higuchi T, Seki N, Kamizono S et al. Polymorphism of the 5′-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 1998 51 : 605 612.
52. Soga Y, Nishimura F, Ohyama H, Maeda H, Takashiba S, Murayama Y. Tumor necrosis factor-alpha gene (TNF-alpha) -1031/-863, -857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese. J. Clin. Periodontol. 2003 30 : 524 531.
53. Taguchi A, Ohmiya N, Shirai K et al. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol. Biomarkers Prev. 2005 14 : 2487 2493.
54. El-Omar EM, Rabkin CS, Gammon MD et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003 124 : 1193 1201.
55. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007 12 : 275 278.
56. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin. Pract. Gastroenterol. Hepatol. 2008 5 : 321 331.
57. Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RC Jr. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 1989 8 : 888 889.
58. Goddard AF, Jessa MJ, Barrett DA et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996 111 : 358 367.
59. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 1998 43 (Suppl. 1 S56 60.
60. Labenz J, Stolte M, Blum AL et al. Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: A study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995 37 : 39 43.
61. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: High-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 2008 28 : 868 877.
62. Furuta T, Shirai N, Xiao F et al. High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 2003 50 : 2274 2278.
63. Sugimoto M, Furuta T, Shirai N et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin. Pharmacol. Ther. 2004 76 : 290 301.
64. Ishizaki T, Horai Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. 1999 13 (Suppl. 3 27 36.
65. Shirai N, Furuta T, Moriyama Y et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment. Pharmacol. Ther. 2001 15 : 1929 1937. (Pubitemid 34014349)
66. Shirai N, Furuta T, Xiao F et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment. Pharmacol. Ther. 2002 16 : 837 846.
67. Furuta T, Shirai N, Takashima M et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 2001 69 : 158 168. (Pubitemid 32225416)
68. Ishida Y, Goto Y, Kondo T et al. Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A. Int. J. Med. Sci. 2006 3 : 135 140.
69. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 1991 174 : 1209 1220.
70. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders. Gastroenterology 2000 118 : 655 660.
71. van der Hulst RW, van der Ende A, Dekker FW et al. Effect of Helicobacter pylori eradication on gastritis in relation to cagA: A prospective 1-year follow-up study. Gastroenterology 1997 113 : 25 30.
72. De Francesco V, Zullo A, Margiotta M et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment. Pharmacol. Ther. 2004 19 : 407 414.
73. Bayerdorffer E, Miehlke S, Mannes GA et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995 108 : 1412 1417.
74. Okudaira K, Furuta T, Shirai N, Sugimoto M, Miura S. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. Aliment. Pharmacol. Ther. 2005 21 : 491 497.